Cargando…

Nanoantibodies: small molecules, big possibilities

Camelids (camels, dromedaries, alpacas, llamas, and vicuñas) contain in their serum conventional heterodimeric antibodies as well as antibodies with no light chains (L) in their structure and composed of only heavy chains (H), called as HcAbs (heavy chain antibodies). Variable fragments derived from...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedreáñez, Adriana, Mosquera-Sulbarán, Jesús, Muñóz, Nelson, Tene, Diego, Robalino, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645571/
https://www.ncbi.nlm.nih.gov/pubmed/36606147
http://dx.doi.org/10.5114/bta.2021.108724
_version_ 1784826990761607168
author Pedreáñez, Adriana
Mosquera-Sulbarán, Jesús
Muñóz, Nelson
Tene, Diego
Robalino, Jorge
author_facet Pedreáñez, Adriana
Mosquera-Sulbarán, Jesús
Muñóz, Nelson
Tene, Diego
Robalino, Jorge
author_sort Pedreáñez, Adriana
collection PubMed
description Camelids (camels, dromedaries, alpacas, llamas, and vicuñas) contain in their serum conventional heterodimeric antibodies as well as antibodies with no light chains (L) in their structure and composed of only heavy chains (H), called as HcAbs (heavy chain antibodies). Variable fragments derived from these antibodies, called as VHH or nanoantibodies (Nbs), have also been described. Since their discovery, Nbs have been widely used in the fields of research, diagnostics, and pharmacotherapy. Despite being approximately one-tenth the size of a conventional antibody, they retain similar specificity and affinity to conventional antibodies and are much easier to clone and manipulate. Their unique properties such as small size, high stability, strong antigen binding affinity, water solubility, and natural origin make them suitable for the development of biopharmaceuticals and nanoreagents. The present review aims to describe the main structural and biochemical characteristics of these antibodies and to provide an update on their applications in research, biotechnology, and medicine. For this purpose, an exhaustive search of the biomedical literature was performed in the following databases: Medline (PubMed), Google Scholar, and ScienceDirect. Meta-analyses, observational studies, review articles, and clinical guidelines were reviewed. Only original articles were considered to assess the quality of the evidence.
format Online
Article
Text
id pubmed-9645571
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-96455712023-01-04 Nanoantibodies: small molecules, big possibilities Pedreáñez, Adriana Mosquera-Sulbarán, Jesús Muñóz, Nelson Tene, Diego Robalino, Jorge BioTechnologia (Pozn) Reviews Papers Camelids (camels, dromedaries, alpacas, llamas, and vicuñas) contain in their serum conventional heterodimeric antibodies as well as antibodies with no light chains (L) in their structure and composed of only heavy chains (H), called as HcAbs (heavy chain antibodies). Variable fragments derived from these antibodies, called as VHH or nanoantibodies (Nbs), have also been described. Since their discovery, Nbs have been widely used in the fields of research, diagnostics, and pharmacotherapy. Despite being approximately one-tenth the size of a conventional antibody, they retain similar specificity and affinity to conventional antibodies and are much easier to clone and manipulate. Their unique properties such as small size, high stability, strong antigen binding affinity, water solubility, and natural origin make them suitable for the development of biopharmaceuticals and nanoreagents. The present review aims to describe the main structural and biochemical characteristics of these antibodies and to provide an update on their applications in research, biotechnology, and medicine. For this purpose, an exhaustive search of the biomedical literature was performed in the following databases: Medline (PubMed), Google Scholar, and ScienceDirect. Meta-analyses, observational studies, review articles, and clinical guidelines were reviewed. Only original articles were considered to assess the quality of the evidence. Termedia Publishing House 2021-09-30 /pmc/articles/PMC9645571/ /pubmed/36606147 http://dx.doi.org/10.5114/bta.2021.108724 Text en © 2021 Institute of Bioorganic Chemistry, Polish Academy of Sciences https://creativecommons.org/licenses/by-nc-nd/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), allowing third parties to download and share its works but not commercially purposes or to create derivative works.
spellingShingle Reviews Papers
Pedreáñez, Adriana
Mosquera-Sulbarán, Jesús
Muñóz, Nelson
Tene, Diego
Robalino, Jorge
Nanoantibodies: small molecules, big possibilities
title Nanoantibodies: small molecules, big possibilities
title_full Nanoantibodies: small molecules, big possibilities
title_fullStr Nanoantibodies: small molecules, big possibilities
title_full_unstemmed Nanoantibodies: small molecules, big possibilities
title_short Nanoantibodies: small molecules, big possibilities
title_sort nanoantibodies: small molecules, big possibilities
topic Reviews Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645571/
https://www.ncbi.nlm.nih.gov/pubmed/36606147
http://dx.doi.org/10.5114/bta.2021.108724
work_keys_str_mv AT pedreanezadriana nanoantibodiessmallmoleculesbigpossibilities
AT mosquerasulbaranjesus nanoantibodiessmallmoleculesbigpossibilities
AT munoznelson nanoantibodiessmallmoleculesbigpossibilities
AT tenediego nanoantibodiessmallmoleculesbigpossibilities
AT robalinojorge nanoantibodiessmallmoleculesbigpossibilities